Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results, Beats Expectations By $0.14 EPS

Vir Biotechnology (NASDAQ:VIR) announced its quarterly earnings results on Wednesday. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14, FiscalAI reports. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 31.80%. The firm had revenue of $238.95 million during the quarter, compared to analyst estimates of $135.88 million. During the same period in the previous year, the business posted ($0.80) earnings per share. The business’s revenue for the quarter was up 19582.5% on a year-over-year basis.

Here are the key takeaways from Vir Biotechnology’s conference call:

• Hepatitis delta efficacy data remained strong: In the 96-week SOLSTICE analysis, 88% of patients receiving elebsiran plus tobevibart achieved undetectable virus versus 53% with tobevibart alone, alongside durable ALT improvements and no treatment-related serious adverse events or discontinuations.
• Vir completed enrollment in all three registrational ECLIPSE studies, with topline data expected from ECLIPSE 1 in the fourth quarter of 2026 and ECLIPSE 2 and 3 in the first quarter of 2027. The company highlighted ECLIPSE 2’s bulevirtide-switch data as a potential launch differentiator.
• The oncology pipeline advanced rapidly following the Astellas collaboration, with VIR-5500 enrolling multiple monotherapy and combination expansion cohorts and potential phase III trials targeted for 2027. Additional data from HER2-targeted VIR-5818 are expected in the second half of 2026.
• Vir ended the quarter with approximately $1.01 billion in cash, cash equivalents, and investments after receiving $315 million from Astellas, extending projected cash runway into the second half of 2028.
• Management acknowledged ongoing senior leadership recruitment, including searches for a new chief medical officer and chief financial officer, while the company continues to manage simultaneous hepatitis delta and oncology development programs.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock traded up $0.12 on Friday, reaching $8.89. The company had a trading volume of 539,492 shares, compared to its average volume of 2,529,587. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -4.78 and a beta of 1.66. The firm’s 50-day moving average price is $9.31 and its two-hundred day moving average price is $9.04. Vir Biotechnology has a 1 year low of $4.16 and a 1 year high of $11.66.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Morgan Stanley set a $25.00 target price on shares of Vir Biotechnology in a research report on Thursday. Wall Street Zen cut Vir Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. Finally, Leerink Partners upped their price target on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.62.

Insiders Place Their Bets

In related news, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the completion of the sale, the director directly owned 21,216 shares in the company, valued at $200,491.20. This trade represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Vir Biotechnology

Several institutional investors have recently made changes to their positions in the company. GSK plc bought a new position in Vir Biotechnology during the 4th quarter valued at about $51,562,000. State Street Corp lifted its stake in Vir Biotechnology by 18.9% in the fourth quarter. State Street Corp now owns 6,229,555 shares of the company’s stock worth $37,564,000 after purchasing an additional 988,262 shares during the last quarter. Orbimed Advisors LLC lifted its stake in Vir Biotechnology by 5.9% in the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock worth $11,999,000 after purchasing an additional 132,466 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Vir Biotechnology by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock valued at $14,041,000 after buying an additional 81,985 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Vir Biotechnology by 3.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,568,904 shares of the company’s stock valued at $9,460,000 after buying an additional 47,102 shares during the period. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.